Clinical observation study of 5-year survivals in patients with newly diagnosed acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan Adult Leukemia Study Group

Clinical observation study of 5-year survivals in patients with newly diagnosed acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan Adult Leukemia Study Group - JALSG AML/MDS/CMML Clinical Observational Study (JALSG-CS)-11

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008371

Enrollment

6100

Registered

2012-07-20

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed AML, MDS, and CMML

Exclusion criteria

Exclusion criteria: Past history of chemotherapy or stem cell transplantation in the treatment of AML, MDS, or CMML

Design outcomes

Primary

Measure	Time frame
(1)AML patient 5-year survivals (2)MDS patient 5-year survivals (3)CMML patient 5-year survivals (4) Usage conditions and efficacy of new agents (lenalidomide and DNMT inhibitors) in MDS patients (5))Numbers of patients with AML, MDS, CMML by age group, sex and type of diseases (6)Feasibility of classification according to known prognostic factors in AML, MDS, CMML. (7)Comparison of survivals between patients enrolled in AML209 study and not enrolled. (8)Usage conditions and efficacy of new agents (DNMT inhibitors) in CMML patients	—

Measure

Time frame

(1)AML patient 5-year survivals (2)MDS patient 5-year survivals (3)CMML patient 5-year survivals (4) Usage conditions and efficacy of new agents (lenalidomide and DNMT inhibitors) in MDS patients (5))Numbers of patients with AML, MDS, CMML by age group, sex and type of diseases (6)Feasibility of classification according to known prognostic factors in AML, MDS, CMML. (7)Comparison of survivals between patients enrolled in AML209 study and not enrolled. (8)Usage conditions and efficacy of new agents (DNMT inhibitors) in CMML patients

—

Secondary

Measure	Time frame
(1) Efficacy of DNMT inhibitors in lower risk MDS (IPSS low/Int-1 risk) (2) Frequency of Erythropoiesis-stimulating agent (ESA) use.	—

Countries

Japan

Contacts

Public ContactKensuke Usuki

NTT Medical Center Tokyo Division of Hematology

kensuke.usuki@gmail.com03-3448-6584

Outcome results